Pyrazolo[1,5-a]Pyridine RET Inhibitor for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small-molecule kinase inhibitors targeting RET protein lack selectivity, leading to pharmacodynamics and pharmacovigilance issues, limiting their effectiveness in treating tumors with abnormal RET activation.
Innovation Solution
Development of a pyrazolo[1,5-a]pyridine derivative with specific structural features that selectively inhibit RET kinase activity, formulated as a pharmaceutical compound for targeted cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current small-molecule kinase inhibitors are used to target RET protein, then RET kinase activity is inhibited, but selectivity is insufficient leading to pharmacodynamics and pharmacovigilance problems
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions on the pyrazolo[1,5-a]pyridine core structure. The compound features specific substitutions at positions 3, 4, and 6 of the pyrazolo[1,5-a]pyridine ring, including electron-withdrawing groups like cyano and heteroaryl groups, which locally modify the molecule's electronic and steric properties to achieve selective binding to RET kinase while avoiding off-target effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the pyrazolo[1,5-a]pyridine derivative. Specific parameters include the type of substituents (R1-R6), their positions, and the nature of linkers (L1, L2), which are optimized to tune the compound's affinity and selectivity for RET kinase. The defined structural constraints (e.g., R1 and R2 forming heterocyclyl, specific L1/L2 options) represent controlled parameter variations to achieve the desired pharmacological profile.
2Adaptability or versatility
If non-selective kinase inhibitors are used, then broad kinase activity is suppressed, but pharmacovigilance issues arise due to lack of RET-specific inhibition
Solution Approach 1:
The patent uses the pyrazolo[1,5-a]pyridine derivative as a selective intermediary compound that specifically mediates inhibition of RET kinase while sparing other kinases. The molecular structure acts as a mediator with optimized pharmacophore features including the heteroaryl substituents and specific linker configurations that enable selective interaction with RET's ATP-binding pocket, thereby achieving RET-specific inhibition without broad kinase suppression.
3Reliability
If existing RET inhibitors are used, then some inhibitory activity is achieved, but efficacy is limited due to insufficient selectivity
Solution Approach 1:
The patent constructs a composite molecular structure by combining the pyrazolo[1,5-a]pyridine core with multiple functional substituents including heteroaryl groups, electron-withdrawing groups, and specific linker moieties. This composite structure integrates multiple pharmacophoric elements that work synergistically: the core provides the binding scaffold, while the substituents (R1-R6) and linkers (L1, L2) contribute to selective recognition and high-affinity binding to RET kinase, thereby achieving both inhibitory activity and structural specificity.
Data Source
AI summary
A pyrazolo[1,5-a]pyridine derivative, and a preparation method and medical use thereof are provided. The pyrazolo[1,5-a]pyridine derivative shown in general formula (I), a preparation method of the derivative, a pharmaceutically acceptable salt of the derivative, and use of the derivative or salt as a therapeutic agent, especially as a rearranged during transfection (RET) inhibitor, are provided.